FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3017046219> ?p ?o ?g. }

• W3017046219 endingPage "3967" @default.
• W3017046219 startingPage "3960" @default.
• W3017046219 abstract "This study investigated the concentrations and seroprevalence of immunoglobulin G (IgG) antibodies against pertussis, diphtheria, tetanus, measles, mumps and rubella among children in Guangzhou, China. We conducted a cross-sectional study focusing on the post-vaccination immune statuses of children on scheduled immunisation. Human IgG antibody against six diseases were measured using commercial enzyme-linked immunosorbent assay kits. Of 620 subjects, the male-to-female ratio was 2.04 (416/204). Seroprevalence (81.97% vs 90.20%) and IgG concentrations (686.55 IU/mL vs 884.26 IU/mL, P < 0.05) for measles, tetanus (0.94 IU/mL vs 1.21 IU/mL) and rubella (34.33 IU/mL vs 47.37 IU/mL) were all higher in females. No differences based on sex were observed in the seroprevalence and IgG concentrations for anti-pertussis antibodies, anti-diphtheria antibodies and anti-mumps. Slight increase in seroprevalence and IgG concentration occurred with anti-pertussis antibodies after primary and booster vaccinations (from 0.00% [1 m], 5.45% [6 m], to 17.14% [1.5 yr]; and from 8.57% [5 yr] to 15.79% [6 yr]). Although no booster vaccination was given after age 6 yr, the seroprevalence and IgG concentration for anti-pertussis antibodies remained relatively stable. For diphtheria, tetanus, measles and rubella, seroprevalence reached their peaks after the primary and first booster vaccination. A plateau occurred after age 1.5 yr with a declining trend in subjects >8–10 yr. The IgG concentrations of these 4 pathogens showed a dramatic increase after primary vaccination, with steadily declining trends thereafter. For mumps, subjects showed increased seroprevalence and IgG concentration after the primary mumps-containing vaccination in 1.5-yr-olds (from 7.14% to 57.14%; 52.13 IU/mL to 214.18 IU/mL); however, following that low seroprevalence levels (from 42.86% to 80.00%) were observed. The post-vaccination immune statuses against diphtheria, tetanus, measles and rubella were relatively satisfactory, compared to those against pertussis and mumps. Booster vaccination against pertussis and mumps at appropriate time should be considered." @default.
• W3017046219 created "2020-04-24" @default.
• W3017046219 creator A5015348751 @default.
• W3017046219 creator A5038060408 @default.
• W3017046219 creator A5049793271 @default.
• W3017046219 creator A5055462963 @default.
• W3017046219 creator A5069378809 @default.
• W3017046219 creator A5082079047 @default.
• W3017046219 creator A5082586077 @default.
• W3017046219 creator A5087517129 @default.
• W3017046219 date "2020-05-01" @default.
• W3017046219 modified "2023-09-23" @default.
• W3017046219 title "Seroprevalences of antibodies against pertussis, diphtheria, tetanus, measles, mumps and rubella: A cross-sectional study in children following vaccination procedure in Guangzhou, China" @default.
• W3017046219 cites W1829488526 @default.
• W3017046219 cites W1897882347 @default.
• W3017046219 cites W1965207731 @default.
• W3017046219 cites W1979756210 @default.
• W3017046219 cites W2005478310 @default.
• W3017046219 cites W2006610286 @default.
• W3017046219 cites W2012151421 @default.
• W3017046219 cites W2015457026 @default.
• W3017046219 cites W2016365670 @default.
• W3017046219 cites W2016418071 @default.
• W3017046219 cites W2025821286 @default.
• W3017046219 cites W2043148249 @default.
• W3017046219 cites W2051037460 @default.
• W3017046219 cites W2051144547 @default.
• W3017046219 cites W2084143009 @default.
• W3017046219 cites W2085105373 @default.
• W3017046219 cites W2093064567 @default.
• W3017046219 cites W2110299699 @default.
• W3017046219 cites W2128666074 @default.
• W3017046219 cites W2128689996 @default.
• W3017046219 cites W2131643987 @default.
• W3017046219 cites W2146836316 @default.
• W3017046219 cites W2152809681 @default.
• W3017046219 cites W2160235724 @default.
• W3017046219 cites W2260237638 @default.
• W3017046219 cites W2260347087 @default.
• W3017046219 cites W2286109734 @default.
• W3017046219 cites W2294639738 @default.
• W3017046219 cites W2338100565 @default.
• W3017046219 cites W2346580711 @default.
• W3017046219 cites W2415662413 @default.
• W3017046219 cites W2603395538 @default.
• W3017046219 cites W2605038128 @default.
• W3017046219 cites W2621417631 @default.
• W3017046219 cites W2737267108 @default.
• W3017046219 cites W2903521218 @default.
• W3017046219 doi "https://doi.org/10.1016/j.vaccine.2020.03.056" @default.
• W3017046219 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32321685" @default.
• W3017046219 hasPublicationYear "2020" @default.
• W3017046219 type Work @default.
• W3017046219 sameAs 3017046219 @default.
• W3017046219 citedByCount "4" @default.
• W3017046219 countsByYear W30170462192022 @default.
• W3017046219 countsByYear W30170462192023 @default.
• W3017046219 crossrefType "journal-article" @default.
• W3017046219 hasAuthorship W3017046219A5015348751 @default.
• W3017046219 hasAuthorship W3017046219A5038060408 @default.
• W3017046219 hasAuthorship W3017046219A5049793271 @default.
• W3017046219 hasAuthorship W3017046219A5055462963 @default.
• W3017046219 hasAuthorship W3017046219A5069378809 @default.
• W3017046219 hasAuthorship W3017046219A5082079047 @default.
• W3017046219 hasAuthorship W3017046219A5082586077 @default.
• W3017046219 hasAuthorship W3017046219A5087517129 @default.
• W3017046219 hasConcept C12590561 @default.
• W3017046219 hasConcept C159047783 @default.
• W3017046219 hasConcept C159654299 @default.
• W3017046219 hasConcept C203014093 @default.
• W3017046219 hasConcept C22070199 @default.
• W3017046219 hasConcept C2776438120 @default.
• W3017046219 hasConcept C2778494684 @default.
• W3017046219 hasConcept C2778814567 @default.
• W3017046219 hasConcept C2779214499 @default.
• W3017046219 hasConcept C2779841045 @default.
• W3017046219 hasConcept C2780572238 @default.
• W3017046219 hasConcept C2780801004 @default.
• W3017046219 hasConcept C2780898057 @default.
• W3017046219 hasConcept C45189115 @default.
• W3017046219 hasConcept C71924100 @default.
• W3017046219 hasConceptScore W3017046219C12590561 @default.
• W3017046219 hasConceptScore W3017046219C159047783 @default.
• W3017046219 hasConceptScore W3017046219C159654299 @default.
• W3017046219 hasConceptScore W3017046219C203014093 @default.
• W3017046219 hasConceptScore W3017046219C22070199 @default.
• W3017046219 hasConceptScore W3017046219C2776438120 @default.
• W3017046219 hasConceptScore W3017046219C2778494684 @default.
• W3017046219 hasConceptScore W3017046219C2778814567 @default.
• W3017046219 hasConceptScore W3017046219C2779214499 @default.
• W3017046219 hasConceptScore W3017046219C2779841045 @default.
• W3017046219 hasConceptScore W3017046219C2780572238 @default.
• W3017046219 hasConceptScore W3017046219C2780801004 @default.
• W3017046219 hasConceptScore W3017046219C2780898057 @default.
• W3017046219 hasConceptScore W3017046219C45189115 @default.
• W3017046219 hasConceptScore W3017046219C71924100 @default.
• W3017046219 hasIssue "23" @default.
• W3017046219 hasLocation W30170462191 @default.

• next